Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Amicus Therapeutics Inc’s stock clocked out at $7.99, down -0.37% from its previous closing price of $8.02. In other words, the price has decreased by -$0.37 from its previous closing price. On the day, 5.46 million shares were traded. FOLD stock price reached its highest trading level at $8.19 during the session, while it also had its lowest trading level at $7.99.
Ratios:
To gain a deeper understanding of FOLD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.29 and its Current Ratio is at 3.21. In the meantime, Its Debt-to-Equity ratio is 2.17 whereas as Long-Term Debt/Eq ratio is at 2.13.
On December 13, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $17 to $12. On September 06, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $18.Jefferies initiated its Buy rating on September 06, 2024, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 19 ’25 when Campbell Bradley L sold 400 shares for $10.00 per share. The transaction valued at 4,000 led to the insider holds 1,150,657 shares of the business.
BRADLEY CAMPBELL bought 400 shares of FOLD for $3,940 on Feb 19 ’25. On Dec 02 ’24, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 7,500 shares for $10.02 each. As a result, the insider received 75,124 and left with 886,654 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 2462829568 and an Enterprise Value of 2675149568. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.31 while its Price-to-Book (P/B) ratio in mrq is 12.05. Its current Enterprise Value per Revenue stands at 4.684 whereas that against EBITDA is 81.191.
Stock Price History:
The Beta on a monthly basis for FOLD is 0.55, which has changed by -0.305821 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, FOLD has reached a high of $12.65, while it has fallen to a 52-week low of $5.51. The 50-Day Moving Average of the stock is 19.24%, while the 200-Day Moving Average is calculated to be 1.42%.
Shares Statistics:
It appears that FOLD traded 4.59M shares on average per day over the past three months and 4071270 shares per day over the past ten days. A total of 308.06M shares are outstanding, with a floating share count of 300.70M. Insiders hold about 2.61% of the company’s shares, while institutions hold 103.02% stake in the company. Shares short for FOLD as of 1755216000 were 21476797 with a Short Ratio of 4.68, compared to 1752537600 on 21727135. Therefore, it implies a Short% of Shares Outstanding of 21476797 and a Short% of Float of 7.01.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Amicus Therapeutics Inc (FOLD).The consensus estimate for the next quarter is $0.17, with high estimates of $0.18 and low estimates of $0.16.
Analysts are recommending an EPS of between $0.35 and $0.3 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.68, with 5.0 analysts recommending between $0.75 and $0.62.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $165.16M. It ranges from a high estimate of $168.87M to a low estimate of $161M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $141.52MFor the next quarter, 11 analysts are estimating revenue of $181.28M. There is a high estimate of $188.23M for the next quarter, whereas the lowest estimate is $175.31M.
A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $637.01M, while the lowest revenue estimate was $619.39M, resulting in an average revenue estimate of $626.6M. In the same quarter a year ago, actual revenue was $528.29MBased on 12 analysts’ estimates, the company’s revenue will be $756.6M in the next fiscal year. The high estimate is $780.26M and the low estimate is $730.96M.
